# Hartfalenprevalentie en -progressie bij type-2-diabetes in hoog risicokader — HF-LANDMARK

*geplaatst 2026-09-16 · Hartfalen · Journal of diabetes and its complications · doi 10.1016/j.jdiacomp.2026.109396 · https://hartvaat.nl/2026/10/01/hartfalenprevalentie-en-progressie-bij-type-2-diabetes-in-hoog-risicokader-hf-la/*

In een prospectieve cohortstudie van 241 patiënten met type-2-diabetes en hoog cardiovasculair risico bleek slechts 0,8% symptomatisch hartfalen te hebben, terwijl 91,3% in stadium A en 7,9% in stadium B verkeerde. Gedurende twee jaar evolueerde 2,8% naar symptomatisch hartfalen, met een incidentie van 0,44 per 100 patiëntjaren bij patiënten met preklinisch hartfalen. Hoewel de lage progressie wijst op effectieve huidige zorg, onderstreept het hoge aantal zorgcontacten de noodzaak om preventieve hartfalenstrategieën systematischer in te zetten bij diabetespatiënten.

## English: Prevalence and evolution of heart failure in patients with type 2 diabetes mellitus at high cardiovascular risk (HF-LANDMARK study).

A 2-year prospective cohort study of 241 outpatients with type 2 diabetes and high cardiovascular risk found that only 0.8% had symptomatic heart failure, while 91.3% were in stage A and 7.9% in stage B. Disease progression to symptomatic heart failure occurred in 2.8% of patients, with an incidence rate of 0.44 per 100 patient-years among those with preclinical disease. Although the low progression rate suggests current monitoring is effective, the high burden of cardiovascular healthcare utilization highlights an unmet need for more systematic preventive heart failure strategies in this population.

## Abstract (original, from the publication)

AIMS: To estimate the prevalence of undiagnosed, symptomatic heart failure (HF) and progression of HF in a contemporary cohort of patients with type 2 diabetes (T2D). METHODS: This was an epidemiologic, 2-year prospective cohort study that enrolled outpatients with T2D, diagnosed within the prior 10 years, with high/very high cardiovascular risk but no HF history. Prevalence and incidence of symptomatic HF (ACC/AHA stages C/D) and cardiovascular-related healthcare resource utilization (HCRU) rates were estimated. RESULTS: From 20-Jul-2020 to 31-Oct-2022, 241 consecutive patients [61.8% males, median (IQR) age 63.0 (57.0-69.0) years] were enrolled; 0.8% (95% CI: 0.00-1.98) had symptomatic (stage C) HF; 91.3% (95% CI: 87.73-94.85) stage A and 7.9% (95% CI: 4.48-11.29) stage B HF. During follow-up, 2.8% (6/215) of evaluable patients experienced HF progression [time-to-progression, median (range): 19.8 (5.9-24.1) months]. Incidence rate of symptomatic HF among patients with preclinical (stage A/B) HF at enrollment was 0.44/100 patient-years (95% CI: 0.11-1.77). Cardiovascular-related HCRU were reported by 54.7% (87/159) of patients, corresponding to incidence rate of 51.68 encounters/100 patient-years. CONCLUSIONS: Whereas the low prevalence of symptomatic HF and low rate of HF-progression likely reflect effective monitoring and intervention at preclinical HF stages, the substantial healthcare-burden highlights an unmet need regarding implementation of HF preventive management strategies in patients with T2D.

Auteurs: Christos Georgiou, Vasiliki Bistola, Apostolos Karavidas, Vassilios P Vassilikos, John Kanakakis, Periklis Davlouros, Dimitrios N Tziakas, Ioannis P Alexanian, George Kochiadakis, John Skoularigis, Haralambos Karvounis, Dimitrios Gourlis, Nikolaos Papoutsidakis, Charalambos Vlachopoulos, Effie Polyzogopoulou, John Parissis

---
Bron: Journal of diabetes and its complications, https://doi.org/10.1016/j.jdiacomp.2026.109396. Bijgewerkt 2026-09-10T00:56:54Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.